Notice Regarding Acquisition of Marketing Authorization Holder License for Regenerative Medical Products

—Further Progress in Establishing the Framework for Domestic Marketing of the Stem Cell Product "Stemchymal®" Following Approval—

September 24, 2026

REPROCELL Inc. (the "Company") hereby announces that as of September 18, 2026, the Company has obtained a "License for Marketing Authorization Holder of Regenerative Medical Products" from Kanagawa Prefecture.

As announced in the Company's June 18, 2026 release, "Notice Regarding Application for Marketing Authorization Holder License for Regenerative Medical Products," the Company had applied to Kanagawa Prefecture for this license.

With respect to the regenerative medicine product "Stemchymal®" ("Stemchymal"), for which the Company holds exclusive commercialization rights in Japan, the Company submitted an application on June 24, 2026, for manufacturing and marketing approval in Japan for the use of Stemchymal to suppress the progression of ataxia in patients with spinocerebellar ataxia (SCA3 and SCA6).

With the acquisition of this license, the Company has made further progress in establishing the framework under which, following manufacturing and marketing approval of Stemchymal, it will serve as the Marketing Authorization Holder (MAH) and be responsible for domestic supply. As the MAH, the Company will be responsible for product quality management and post-marketing safety management and will continue preparations for a smooth start of supply following approval.

Obtaining this license represents one of the key milestones toward the domestic launch of Stemchymal.

The Company will continue to make every effort to obtain approval for and launch Stemchymal, aiming to deliver a new treatment option to patients with spinocerebellar ataxia as soon as possible.

The impact of this matter on the Company's financial performance for the current fiscal year is currently expected to be minor; however, should any matters requiring disclosure arise in the future, the Company will promptly disclose them.

Glossary

Marketing Authorization Holder (MAH): This refers to the statutory entity that releases pharmaceuticals and regenerative medical products to the domestic market and bears ultimate legal responsibility for quality management and post-marketing safety management. Obtaining a License for Marketing Authorization Holder from the regulatory authority is legally required to conduct this business.